EMA Authorised: Aucatzyl (obecabtagene autoleucel) — Autolus GmbH

View source ↗

Summary

EMA authorised Aucatzyl (obecabtagene autoleucel) from Autolus GmbH for precursor B-cell lymphoblastic leukemia/lymphoma, under conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Aucatzyl (obecabtagene autoleucel)

Snippet

Status: Authorised. Therapeutic area: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. MAH: Autolus GmbH. Decision date: 17/07/2025. Conditional approval